Patients’ and Healthcare Professionals’ Preferences Regarding Lipid-Lowering Therapies for Patients with Very High Cardiovascular Risk and Established Atherosclerotic Cardiovascular Disease
Author(s)
Parrondo García FJ1, Fernandez Olmo MR2, Álvarez Hermida AB3, Castellanos M4, Gomez Cerezo J5, Igual Guaita MJ6, Jansen Chaparro SJ7, Obaya Rebollar JC8, Martin Mitjana L9, Cosin-Sales J10
1Novartis Spain, Coslada, M, Spain, 2Hospital Universitario de Jaen, Jaen, Jaen, Spain, 3Centro de Salud Goya, Madrid, Madrid, Spain, 4A Coruña University Hospital & Biomedical Research institute, A Coruña, Spain, 5Infanta Sofia University Hospital, Madrid, Spain, 66Farmacia de Atención Primaria del Departamento de Salud de Gandía, Gandía, Valencia, Spain, 7Hospital Regional Universitario de Málaga, Málaga, Málaga, Spain, 8Centro de Salud Chopera, Madrid, Madrid, Spain, 9Novartis Spain, Barcelona, Barcelona, Spain, 10Hospital Arnau de Vilanova, Valencia, Valencia, Spain
Presentation Documents
OBJECTIVES: Controlling LDL cholesterol (LDL-C) can reduce atherosclerotic risk. However, not all available therapies are equally effective and safe, or use the same route of administration. Involving patients and considering their preferences in treatment decision-making can help treatment success. The main goal was to assess patients’ and healthcare professionals’ (HCP) preferences regarding the characteristics (attributes) of lipid-lowering therapies.
METHODS: A discrete choice experiment (DCE) was conducted to determine participants’ preferences. A literature review and two focus groups (patients=4; HCP=8) were conducted to identify the attributes and levels to be included in the DCE; five attributes (safety, medication collection location, LDL-C reduction, prevention of cardiovascular problems, route of administration) with 2-3 levels each were included, resulting in 36 scenarios. The relative importance (RI) given to each attribute was estimated using a conditional logit model.
RESULTS: A total of 42 patients and 89 HCP participated in the study. A third of the patients were women with a mean age of 55.6 years. The most common atherosclerotic cardiovascular disease was myocardial infarction (47.6%) and the most common treatment received was atorvastatin (61.1%). Regarding HCP (primary care: 16.9%; cardiology: 16.9%; neurology: 16.9%: internal medicine: 15.7%; nursing: 16.9%; clinical pharmacy: 16.9%), 42.7% were women, with a mean professional experience of 23.9 years. Most of the HCP (76.4%) worked in hospitals with >300 beds. The estimated RI were: safety: Patients: 24.0%, HCP: 10.2%; medication collection location: Patients: 12.1%, HCP: 9.5%; LDL-C reduction: Patients: 26.8%, HCP: 31.6%; prevention of cardiovascular problems: Patients: 26.8%, HCP: 37.7%; and route of administration: Patients: 10.3%, HCP: 10.9%.
CONCLUSIONS: When selecting a lipid-lowering treatment, patients valued similarly efficacy (LDL-C reduction and prevention of cardiovascular problems) and safety, while HCP considered efficacy the most important attribute, followed by route of administration. The results of the study can contribute to improve decision-making.
Conference/Value in Health Info
Value in Health, Volume 26, Issue 11, S2 (December 2023)
Code
PCR2
Topic
Patient-Centered Research
Topic Subcategory
Patient Behavior and Incentives, Stated Preference & Patient Satisfaction
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory)